Tags

Type your tag names separated by a space and hit enter

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.
Leukemia. 2013 Aug; 27(8):1722-8.L

Abstract

We evaluated the MYD88 L265P mutation in Waldenström's macroglobulinemia (WM) and B-cell lymphoproliferative disorders by specific polymerase chain reaction (PCR) (sensitivity ∼10(-3)). No mutation was seen in normal donors, while it was present in 101/117 (86%) WM patients, 27/31 (87%) IgM monoclonal gammapathies of uncertain significance (MGUS), 3/14 (21%) splenic marginal zone lymphomas and 9/48 (19%) non-germinal center (GC) diffuse large B-cell lymphomas (DLBCLs). The mutation was absent in all 28 GC-DLBCLs, 13 DLBCLs not subclassified, 35 hairy cell leukemias, 39 chronic lymphocytic leukemias (16 with M-component), 25 IgA or IgG-MGUS, 24 multiple myeloma (3 with an IgM isotype), 6 amyloidosis, 9 lymphoplasmacytic lymphomas and 1 IgM-related neuropathy. Among WM and IgM-MGUS, MYD88 L265P mutation was associated with some differences in clinical and biological characteristics, although usually minor; wild-type MYD88 cases had smaller M-component (1.77 vs 2.72 g/dl, P=0.022), more lymphocytosis (24 vs 5%, P=0.006), higher lactate dehydrogenase level (371 vs 265 UI/L, P=0.002), atypical immunophenotype (CD23-CD27+ +FMC7+ +), less Immunoglobulin Heavy Chain Variable gene (IGHV) somatic hypermutation (57 vs 97%, P=0.012) and less IGHV3-23 gene selection (9 vs 27%, P=0.014). These small differences did not lead to different time to first therapy, response to treatment or progression-free or overall survival.

Authors+Show Affiliations

Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23446312

Citation

Jiménez, C, et al. "MYD88 L265P Is a Marker Highly Characteristic Of, but Not Restricted To, Waldenström's Macroglobulinemia." Leukemia, vol. 27, no. 8, 2013, pp. 1722-8.
Jiménez C, Sebastián E, Chillón MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia. 2013;27(8):1722-8.
Jiménez, C., Sebastián, E., Chillón, M. C., Giraldo, P., Mariano Hernández, J., Escalante, F., González-López, T. J., Aguilera, C., de Coca, A. G., Murillo, I., Alcoceba, M., Balanzategui, A., Sarasquete, M. E., Corral, R., Marín, L. A., Paiva, B., Ocio, E. M., Gutiérrez, N. C., González, M., ... García-Sanz, R. (2013). MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia, 27(8), 1722-8. https://doi.org/10.1038/leu.2013.62
Jiménez C, et al. MYD88 L265P Is a Marker Highly Characteristic Of, but Not Restricted To, Waldenström's Macroglobulinemia. Leukemia. 2013;27(8):1722-8. PubMed PMID: 23446312.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. AU - Jiménez,C, AU - Sebastián,E, AU - Chillón,M C, AU - Giraldo,P, AU - Mariano Hernández,J, AU - Escalante,F, AU - González-López,T J, AU - Aguilera,C, AU - de Coca,A G, AU - Murillo,I, AU - Alcoceba,M, AU - Balanzategui,A, AU - Sarasquete,M E, AU - Corral,R, AU - Marín,L A, AU - Paiva,B, AU - Ocio,E M, AU - Gutiérrez,N C, AU - González,M, AU - San Miguel,J F, AU - García-Sanz,R, Y1 - 2013/02/28/ PY - 2012/12/29/received PY - 2013/02/09/revised PY - 2013/02/13/accepted PY - 2013/3/1/entrez PY - 2013/3/1/pubmed PY - 2013/10/22/medline SP - 1722 EP - 8 JF - Leukemia JO - Leukemia VL - 27 IS - 8 N2 - We evaluated the MYD88 L265P mutation in Waldenström's macroglobulinemia (WM) and B-cell lymphoproliferative disorders by specific polymerase chain reaction (PCR) (sensitivity ∼10(-3)). No mutation was seen in normal donors, while it was present in 101/117 (86%) WM patients, 27/31 (87%) IgM monoclonal gammapathies of uncertain significance (MGUS), 3/14 (21%) splenic marginal zone lymphomas and 9/48 (19%) non-germinal center (GC) diffuse large B-cell lymphomas (DLBCLs). The mutation was absent in all 28 GC-DLBCLs, 13 DLBCLs not subclassified, 35 hairy cell leukemias, 39 chronic lymphocytic leukemias (16 with M-component), 25 IgA or IgG-MGUS, 24 multiple myeloma (3 with an IgM isotype), 6 amyloidosis, 9 lymphoplasmacytic lymphomas and 1 IgM-related neuropathy. Among WM and IgM-MGUS, MYD88 L265P mutation was associated with some differences in clinical and biological characteristics, although usually minor; wild-type MYD88 cases had smaller M-component (1.77 vs 2.72 g/dl, P=0.022), more lymphocytosis (24 vs 5%, P=0.006), higher lactate dehydrogenase level (371 vs 265 UI/L, P=0.002), atypical immunophenotype (CD23-CD27+ +FMC7+ +), less Immunoglobulin Heavy Chain Variable gene (IGHV) somatic hypermutation (57 vs 97%, P=0.012) and less IGHV3-23 gene selection (9 vs 27%, P=0.014). These small differences did not lead to different time to first therapy, response to treatment or progression-free or overall survival. SN - 1476-5551 UR - https://www.unboundmedicine.com/medline/citation/23446312/MYD88_L265P_is_a_marker_highly_characteristic_of_but_not_restricted_to_Waldenström's_macroglobulinemia_ L2 - http://dx.doi.org/10.1038/leu.2013.62 DB - PRIME DP - Unbound Medicine ER -